711 bet bonus code 2024

Liverpool boss Arne Slot talks up ‘special player’ Mohamed Salah

Liverpool boss Arne Slot talks up ‘special player’ Mohamed SalahHouse control won’t last long

Suarez extends Inter Miami stay with new deal

THE MOJ: Lengthy list of coaching candidates as new Lions regime vows toughnessFianna Fail and Fine Gael eye independent TDs as option to secure Dail majorityGoogle needs ‘right conditions’ to build more AI infrastructure in UK

Jo McAlister has been appointed as the new CEO of Initiative Australia , succeeding from Melissa Fein who left the agency earlier this year with Sam Geer and Chris Colter for The Monkeys. McAlister’s appointment heralds a new era of leadership for the agency. She will announce her expanded leadership team shortly. Mark Coad , CEO of IPG Mediabrands Australia, said from the outset he committed to taking the time to carefully canvas the industry nationally and globally in order to find the best person for this pivotal role, which made it all the more gratifying to have found the ideal person already firmly ensconced at the agency. Coad said: “Jo is a highly regarded leader with a strong people-first leadership style, a track record of managing large clients in complex market categories and proven success in data and technology-driven media innovation and marketing. She not only knows Initiative from the inside out – its people, its culture and its clients – but she also has a strong vision for the agency’s future and is eager to set the agenda to drive the next era of Initiative. “The agency has dug deep this year to solidify its positioning as the cultural experience agency, with award-winning work client across multiple markets. Jo has driven the new direction which makes me even more delighted to see her take on this key role, and I look forward to working alongside her and building on Initiative’s longstanding success.” McAlister first joined IPG more than five years ago, leading Rufus (Powered by Initiative) to support Amazon as a new market entrant to achieve significant, sustained sales growth before taking on the role of managing director of Initiative Sydney in 2019. Under her leadership, the Sydney office has won and retained many key clients, including Sanitarium, Fantastic Furniture, Pernod Ricard, Goodman Fielder, Salesforce and IAG. Prior to IPG, McAlister held several senior client-side marketing positions at Foxtel, NBCS, SBS and Seven, the most recent as Content Marketing Director at Foxtel, where she helped produce Cannes Lion-winning work on the final series of Game of Thrones. Throughout her media and client-side career, McAlister has been recognised for her commitment to building strong, high-performing teams, her experience as a former client uniquely positions her to navigate client challenges, which has shaped her approach as a trusted partner and leader. She is known for challenging the status quo to deliver more effective solutions for clients driving sustainable growth and better consumer experiences. Newly appointed CEO Jo McAlister said: “I am honoured to take on this important role and excited about what the future holds for Initiative, our incredibly talented team and our driven clients. I have experienced first-hand the culture of innovation and collaboration that leads to exceptional client work, and I look forward to building on that with my colleagues, collaborating with our many industry partners, and driving significant outcomes for our loyal clients. With my previous client experience I know how to think like a client which underpins my approach and leadership style. “I would also like to acknowledge Initiative’s previous leadership team whom I collaborated closely with for nearly five years, they have left a strong and solid foundation for me to build a new era for the agency. I cannot wait to get started as I am bursting with ideas and new initiatives.” Coad concluded: “As an agency Initiative often says to its team that they will do the best work of their career at Initiative, and as a result their career will flourish ; this mantra has proven true for Jo.” – Top image: Jo McAlisterThe new Airbus H145m aircraft will replace and expand the Air Corps ’ small fleet of light utility helicopters. The services’s two existing EC135 helicopters are approaching the end of their service life and are due to be scrapped in 2027. The Air Corps will take delivery of the new aircraft from Airbus sometime early in 2027 in a deal worth €91.7 million plus VAT. The primary role of the four new helicopters will be training new pilots before they move on to larger aircraft or flying helicopters for the Garda Air Support Unit. [ Army pulls out of Portlaoise Prison after 51 years in wake of IRA clear-out Opens in new window ] However, the H145s will also be capable of “intelligence, surveillance, reconnaissance and light combat capabilities”, the Department of Defence said. They will be capable of supporting Army, naval and Air Corps operations and will be particularly useful for transporting and inserting personnel from the Army Ranger Wing, the Defence Forces elite special forces unit. They will also come fitted with advanced surveillance technology, including electro-optical and thermal-imagery features not available on the existing helicopters. The Airbus deal is part of a planned expansion of Air Corps capabilities as laid out in a report from the Commission on the Defence Forces. Eventually, the organisation will also be renamed the Air Force. [ Officer dismissed from Defence Forces for attempting to interfere with candidate’s application for Army career Opens in new window ] The Government has already announced plans for the purchase of a new Air Corps-operated government jet, with twice the range of the existing ageing model, and a long-range, military-transport aircraft capable of evacuating Irish citizens from trouble spots. There are also plans for the acquisition of larger helicopters, known as super medium helicopters, to replace the Air Corps fleet of six AgustaWestland AW139 aircraft. A military primary radar system to detect maritime and airborne threats is also being planned while work will begin soon on upgrading the airside infrastructure of the Air Corps headquarters at Casement Aerodrome in Baldonnell, Dublin. [ Irish naval ships may have to deploy unarmed as weapons unit down to single technician Opens in new window ] A major challenge for the Defence Forces will be finding enough pilots and technicians to fly and service its new aircraft. Like the rest of the military, the Air Corps’ abilities to carry out missions has been significantly hampered by an exodus of trained personnel to the private sector in recent years. The Air Corps currently has 677 personnel, well below its establishment strength of 886. “The procurement of the Airbus H145M helicopter platform is another important step on the journey of transformative change of our Defence Forces,” said Defence Forces’ Chief of Staff, Lieut Gen Seán Clancy. “These new light multirole helicopters, proven in their service in other militaries, will not only enhance the Irish Air Corps’ rotary capability but will also serve as a critical enabler to the Army, Naval Service and Special Operations Forces.” Air Corps chief Brig Gen Rory O’Connor said the new helicopters “mark a significant milestone” for the organisation. “These helicopters will also play an important role in shaping the next generation of rotary-wing pilots, ensuring the Irish Air Corps remains agile, adaptable, and mission-ready for years to come.” Conor Gallagher is Crime and Security Correspondent of The Irish Times

Making J&K TB-Free

Abandoned mines in the US pose dangers to people and property when land gives way

“The real estate sector’s GDP growth rates in 2024 were relatively subdued, recording 0.84 per cent in Q1, 0.75 per cent in Q2, and 0.68 per cent in Q3. These figures lagged behind the national GDP growth rate for each quarter, underscoring the sector’s challenges,” a report by BuyLetLive read. According to the report, despite this slow growth, the real estate service GDP contribution growth rate remained robust, standing at 5.20 per cent in Q1, 5.17 per cent in Q2, and 5.43 per cent in Q3. It stated, “This consistency highlights the sector’s indispensable role in supporting broader economic activity. Real estate remains a significant contributor to urbanisation, employment generation, and wealth creation, even amid its slower growth. “In comparison, the construction sector showed a more dynamic growth trajectory. After contracting by 2.14 per cent in Q1, the sector rebounded with growth rates of 1.05 per cent in Q2 and 2.91 per cent in Q3. This rebound can be attributed to increased public spending on infrastructure, private sector investments, and heightened demand for both residential and commercial properties. “The construction sector’s GDP contribution growth rate followed a similar path, reflecting the symbiotic relationship between construction and real estate. As construction expands, it creates opportunities for real estate development, while strong demand in real estate stimulates construction activities.” On challenges holding back real estate growth, the report noted that several factors contributed to the real estate sector’s relatively slower growth. It further read, “One of the most significant issues is the economy’s slow recovery from inflationary pressures, which has affected purchasing power and reduced demand for residential and commercial properties. High-interest rates have compounded this problem by making borrowing for real estate projects more expensive. Regulatory hurdles, such as delays in land titling and high transaction costs, also remain significant challenges for the sector. Additionally, the absence of a unified housing policy has created inefficiencies, further stifling growth. Related News LASG calls for innovation in real estate sector US-based real estate firm unveils platform for Nigerian investors High inflation, demolitions hinder $2.4tn real estate value – Operators “Another critical issue is the persistent demand-supply mismatch. Rapid urbanisation continues to drive demand for affordable housing, but supply has not kept pace due to high construction costs, limited access to land, and insufficient financing options. The lack of affordable mortgage systems has further constrained residential real estate growth, leaving a gap that needs urgent attention from policymakers and industry stakeholders. “The implications of these dynamics are significant for various stakeholders in the real estate industry. For policymakers, there is an urgent need to streamline housing regulations, simplify land titling processes, and invest in infrastructure that supports real estate activities. Developers must focus on cost optimisation, innovative construction methods, and exploring emerging markets to overcome rising costs and limited demand. Investors can benefit from leveraging data-driven insights to identify high-potential areas for growth while diversifying their portfolios across residential, commercial, and industrial segments. For consumers, the growing adoption of green building technologies and affordable housing initiatives offers promising opportunities. However, advocacy for transparent pricing and financing options remains crucial to making real estate more accessible to the broader population.” It further stated that despite these challenges, opportunities still abound in the real estate sector. “The construction sector’s growth presents direct opportunities for real estate development, particularly in urban centres like Lagos, Abuja, and Port Harcourt. Public-private partnerships aimed at addressing affordable housing deficits could also unlock significant potential in the residential market. The rise of technology and innovation in the industry offers another avenue for growth. Proptech solutions, such as digital platforms for property transactions, smart home technologies, and data-driven market insights, are creating efficiencies and boosting investor confidence. “Furthermore, the growing focus on sustainability is reshaping real estate development in Nigeria. Green building practices and sustainable real estate solutions are gaining traction as awareness of environmental issues grows. These trends not only enhance the appeal of new developments but also position the industry for long-term relevance in a rapidly changing global market. “Nevertheless, the real estate industry faces persistent challenges that need to be addressed to unlock its full potential. Economic volatility remains a major concern, despite the improving GDP growth rate. Rising costs of building materials, labour, and logistics are straining developers and pushing up property prices, which limits affordability. Additionally, inadequate infrastructure development in rural and peri-urban areas restricts opportunities for real estate expansion, despite the pressing need for housing in these regions. Inconsistent government policies and unclear tax regimes also create uncertainties that deter both local and foreign investors.”49ers QB Brock Purdy remains severely limited by injured throwing shoulder

PROVIDENCE, R.I. – The campus of Butler Hospital is awash in fall colors as the sun moves toward the horizon, on Thursday afternoon, Nov. 7. The shift of nurses, doctors and patients is on the move, the daily changing of the caretakers, as ConvergenceRI struggled on trekking poles to reach the main entrance, on time for an interview with Dr. Linda Carpenter, M.D. One of the pioneering neuroscience researchers at Butler Hospital, Dr. Carpenter is the lead clinical trial researcher on a new, take-home device (Relivion) created by Neurolief to treat major depressive disorder, a chronic and recurring condition that afflicts millions. The interview took place in Dr. Carpenter’s office at Butler Hospital, a portal into a space defined by stylish design and acute attention to detail. Dr. Carpenter is wearing a turquoise scarf that depicts the brain’s synapse structure, replete with dendrites and axons depicted in black. Two days before the interview, former President Donald Trump had been elected the 47th President of the United States, as if the entire nation had been victimized by a mass psychosis where facts no longer seemed to matter. That evening, members of the Rhode Island Senate would convene in a caucus that replicated a medical intervention, as Senators endorsed the continued leadership of Senate President Dominick Ruggerio, despite indications that his chronic health conditions had taken a severe toll. Earlier this summer, ConvergenceRI had conducted an interview with Dr. Carpenter, “Listening to what your brain is telling you,” following her being awarded the Clinical Transcranial Magnetic Stimulation Society Gold Medal. Dr. Carpenter serves as director of the Transcranial Magnetic Stimulation Clinic and Neuromodulation Research Facility at Butler Hospital, a division of Care New England. ConvergenceRI: I am amazed at the latest work, which seems to be just remarkable, in terms of its groundbreaking nature of treatment: The idea that people can have a take-home device that can help them with their treatment of drug-resistant depression. The treatment moves forward in such a way that it may help patients to overcome everything from long-term depression to migraines. CARPENTER: Right. The particular device that we are talking about today which is the subject of clinical trial that we just finished, is the same device that they have already gotten approved for migraines, but the stimulation pattern that it gives for depression is different. You would use this device [taking off her glasses to put on the device to model it], they may look the same, but the stimulation of the prescription , if you will, would be different for migraine than it is for depression. But, it is incredibly exciting, because we don’t yet have any FDA-approved home-use devices for depression. ConvergenceRI: My first question to you is, “How would I be able to get one of these devices?” How would I qualify? Are the clinical trials’ hurdle now over? CARPENTER: The clinical trial was conducted at multiple sites around the country, and I think we also had an Israeli site [the Relivion corporate headquarters are based in Israel with a facility in Florida]. The clinical trial proved the efficacy [of the device] by randomizing people in active or sham, right? The data demonstrated a superior outcome for the people who had active [devices]. At this point, the whole package of results has gone to the FDA, maybe about a month ago. And, they are processing it. Before the FDA started this trial, they gave this company what is known as a “breakthrough designation,” to help them get onto a fast track for going through the regulatory process, because they identified a need for patients with treatment-resistant depression to have [access to a device] at home. Many of [the patients] can’t come to our clinic five days a week for TMS [transcranial modulation stimulation], or they can’t come in for ECT [electro-convulsive therapy]; you would have to have someone drive [the patient] here and then drive them home. The FDA identified the need and put [the firm] on fast track. The company expects, and I don’t work for the company, but I think they expect to receive FDA approval in early 2025. And then, when that happens, they can commercially market the device. Now, how will that work? I don’t know. This is the first of its type, There are a couple different of ways that this can go. It could be that you come to your doctor’s office, they supervise you using it a couple of times until they are confident that you can use it properly. And then you take home the device, use it, come back, check in every two or three or four weeks, something like that. There is also this question of durable medical equipment, which is out of my wheelhouse and how it would work. Which is where you are a clinic and you actually sell the device to the patient. You have a stock of them. I don’t know what the business model will look like. What I do know is that it’s a prescription device . So, you will have to be monitored by a doctor. It doesn’t mean that it has to be a psychiatrist. You could go to a primary care doctor. But, when it first rolls out, because it is FDA-approved for people who have not gotten better with at least one anti-depressant medication, it will b prescribed typically by a psychiatrist at first, I think. And as broadly as it can be disseminated, that would be great. Because the goal would be to reach all of those patients who can’t come to a specialty clinic. And there are a lot of those. If you think about, when we talk about treatment resistant depression, basically about a third of patients don’t get better with standard anti-depressant treatment. And, that’ a huge number; it’s millions of patients, [looking it up on her computer]. There are some 21 million patients with depression, 9 million being treated with anti-depressants, and 3 million meet this criteria for treatment resistant depression if they don’t get better with a standard anti-depressant. We are looking to find and implement a treatment that would be more convenient and accessible – and I am very excited about that. ConvergenceRI: For me as the journalist, the question is: How could I get one of these devices and write about it, and perhaps become part of the follow-up. The goal would be, that as much as a scientific endeavor, I think that for people to understand what is going on, it might be helpful to have a journalist who can write about the experience and share that... CARPENTER: ...It would be fantastic. ConvergenceRI: ...in a comprehensive fashion, I am willing to raise my hand... CARPENTER: ...And volunteer? ConvergenceRI: I would volunteer to become a patient, or whatever is required, to do this, because I think for all the studies you can do, having someone to actually talk about it in a cogent fashion is intriguing to me. CARPENTER : Yes. You can go onto the company’s website and get a prescription for the migraine device. And, I don’t how you do that, I just noticed this (Relivion website for migraine) today, and I think you can purchase it and have it sent to you, and it would be very similar. You would get the experience of what it is like; they have a prescription and then there are accessories. ConvergenceRI: Would that come from through my primary care physician? CARPENTER: I was just looking to see if you could get a prescription under the migraine indication. The trial would go on for 60 days. This is a brand new website, (there is a listing, “Getting started. Telehealth and find a doctor.”) You might b able to interact with this website and get one for a migraine, with a telehealth physician. It looks like they give you ways to do that. ConvergnceRI: I will consider following up with that. From what you have described, it seems like it is a major breakthrough in treatment, with the possibility that this device will be something that will change the way that depression is treated. And perhaps conditions that are linked to depression, such as obsessive compulsive behavior. CARPENTER: Well, we haven’t tested those other indications. But I think you have the right idea. And, in fact, here are a number of devices, if you just Google them, you can find them. But the difference between this and those [other devices] is that they haven’t been put through large, randomized control trials, which takes a lot of time and a lot of money. ConvergenceRI: Have you gone through Phase I, Phase II, and Phase III clinical trials? CARPENTER: The clinical trials design are not the same for drugs as they are for devices. This would be a device that they tested it in an early pilot study. And, they have done all their safety testing before they came to this clinical trial. And, then, I guess, after FDA approval, this is all that will likely be needed according to the FDA to get the clearance. And then, after the clearance, there will be a lot of questions we need to address. We studied this, with people using it every day, active or sham, for a period of eight weeks. And then, what happened in this clinical trial, at the end of eight weeks, you got to crossover and go to active, if you had gotten the sham, and if you had already got active for eight weeks, you could, continue with eight more weeks of active. There were a number of questions built into [the study]. One, if you aren’t all the way better by eight weeks, and you keep going, will you get more people into remission? And, the answer to that question was yes, because more people kept getting better. And the other question was: If you had sham for the first eight weeks, and now you get the real device, can you replicate that the same percent of people were getting better, and we did. But some of the questions we haven’t answered are: OK, we’ve had people using the device for up to 16 weeks, what does the maintenance look like? Do you stop using it? Do you continue to use it? Do you continue to use it less often? How long will it last? Is it something that you are going to pick up when you start to slip and your [depressive] symptoms start to come up again? As soon as the FDA approval happens, then those will be next types of studies that we are doing. And also, we will be doing more mechanism of action studies. To do scans, before and after treatment, to look at how is it changing connections in the brain, and the way it does. ConvergenceRI: How has it changed your life? You have spent a large amount of time working on this, to see it come to creation. To now have a device that is sitting on front of you on your desk, and it seems to work, what is that like for you as a researcher, as a neuroscientist? CARPENTER: It is really exciting. I am very big on “the bench to bedside.” Getting all the way to implementation is something that I really, really enjoy. You know, a few of the hurdles that lay ahead are that this is a small, start-up company that is looking for a big company such as Pfizer to buy them and co-license it to help facilitate the next bunch of clinical trials that need to happen to answer all these additional questions. A lot of this is now in the hands of the device manufacturer, to take the next big steps to help get the device out there. I’m thrilled to be able to talk about it. I am thrilled to know that it works and to recommend it. But, access is so important. And, like all these other new treatments, if people can’t afford them, if health insurance doesn’t cover it... There needs to be access. I am just really hopeful that the pieces fall into place and that they are taken care of, because that is not [the focus of] my work. My work is the scientific work. To get it to implementation, so I can see patients using it. And not just in my clinical trials. We want people to be able to be use it; I think that will take some time. To answer your question directly, there is a little bit of antsy-ness about wanting to keep moving forward, and doing the next thing, to get their money and to get their companies and their commercial model all built. But, it’s exciting. It’s exciting to have been a part of designing the trial to help pick the sites, and make sure that it was conducted with scientific rigor. And to have good data. Because, you know, there are a number of devices out there. Congess passed a law in 1972 that said the FDA will regulate medical devices. And, ever since then, all the biomedical devices go through FDA. But, there were a bunch of devices on the market before 1972. And they were grandfathered in. They have been able to market themselves legally, without ever doing clinical trials, So there are all these devices that patients can get that they advertise for depression or for anxiety or pain, or to improve your dreaming, or something. But they just don’t have the science behind them. Psychiatrists and other physicians tend not to prescribe them; patients sometimes find them and ask, “Will you sign this form I got online?” But they haven’t really been incorporated into the mainstream of treatment because they haven’t had the science. So now, we have the first one with the science. And that is really exciting. I would like to see it become used as a regular treatment for depression. ConvergenceRI: What does it feel like for you to be able to help direct the first of its kind device with the promise of something to be so helpful to people, who are often struggling to get by day-today? CARPENTER: It feels great. It feels really great. We all want to do something, you work with patients, and you are experiencing their suffering, and the disabling nature of the depression. And, the problems with side effects. And, the burdens on families and the economy. It feels great to have something. It will feel greater when I can go, here you are. There are so many people who were involved with the device. I didn’t design it; I didn’t invent it. And, the company did really elegant work in putting it together. It has a really elegant interaction with your smart phone that walks you through how to use it, that checks to make sure that the device is on right, and that sends the information to the cloud that I can look at on a dashboard to see if the patient is using the device safely. But, you know, we are not completely at the finish line until it is disseminated. ConvergenceRI: Let me go back and ask about what is actually happening in the brain with the device. And please correct me if I get this wrong. The idea is what you are working with is the way that the brain can reconfigure the way that the synapses and the neurons fire, essentially that there is a learned pattern that takes place, so if you fire the sequence enough times, it becomes the learned pattern in the brain, and it doesn’t go back to all of the intermediate steps. It goes from A to F, without having gone through B, C, D, and E to get to F. What the device seems to be doing is retraining , if that is the right “verb” to use, to get the neurons to fire differently. CARPENTER: Right. ConvergenceRI: To take the “memories” that are contained, if “memory” is the right word, of what gets lost in the translation of the firing of the synapse. Is that accurate? CARPENTER: That’s a good way to think about it. Think about it like a computer. The computer has all these different parts that have to interact and, if one part breaks down, then the other parts might go around that part. This part might have the control of that part, like a circuit board. Think of depression like a circuit board. And just like you said, A, B, C, and D. And the circuits are connected by synapses, neurons and synapses, right? And so, like you said, if the part of the reward center and joy is turned off and not coming on, and the fear center and anxiety is on when it shouldn’t be, and the top control isn’t telling the others this isn’t the time to be anxious. This isn’t the time to be turned off, this isn’t the time to be attending – all those different signals. So, we know that there are these functional changes in the brain when someone is depressed. And, by and large, you can see when people get better, although depression has a lot of different versions, right? There are a lot of different versions of depression. If you look at all the different symptoms, and there are lot of different ways that it can look. But, in general, if you think about circuit pathology , that the circuit Is not working properly... ConvergenceRI: Circuit pathology? CARPENTER: Yes. Again, if I have a lot of anxiety in my depression, then my amygdala, its connections to other things are not being regulated. We want our brain to say, “Oh yes, be fearful,” when it is appropriate to be fearful, when you are in a terribly dangerous situation. But not when you are trying to relax, and your reward center should be able to turn on when you experience certain things. And so, negative old memories should stay put, and not come in and re-evaluate what is happening in the present, The question of how the device’s treatment for depression works to fix that is unanswerable. How does psychotherapy fix that? How does ECT fix that? How does medication fix that? What we know is where the device has its actions. Or where EMS has its actions. Or what Prozac sticks to on the molecule, right? And what we know about this device is that it stimulates some peripheral nerves, branches of nerves called the trigeminal nerve in the front and branches of these nerves in the back, and these are right underneath your skin, these nerves are stimulated in this synchronous way, carrying messages down to the brain stem. And, this goes up through a bunch of connections, the solitary tech nucleus, the hypothalamus, and gets into the nodes, as you will, of the circuit. How that fixes the regulation is the question. ConvergenceRI: Am I asking the right questions? CARPENTER: Oh, yes, I think they are great questions. ConvergenceRI: Thanks. Trying to translate what you are saying into language that people can understand, that’s part of the problem. I think I get some of it. But I am very much in awe of what it takes to translate what is happening, and the way that you then see it. There is clearly a difference between causation and correlation. CARPENTER: Just think about Prozac’s impact on the serotonin uptake inhibitors And people said: It sticks on this little thing on the cell and it causes more serotonin to be in the cell. It’s not like we’re all down a quart of serotonin; it still is changing the circuits and how they talk to each other. And sometimes, we act like we know exactly how a treatment works. How does psychotherapy work? And that is really a retraining right? Forcefully creating new habits. ConvergenceRI: How tied into other senses is this work? With psychotherapy, you have to listen. In terms of drug intake, it is all about modulating how we respond to pleasure, versus things that are not pleasurable, and the wirings that enable that to happen. CARPENTER: That’s the black box, the wiring that enables it to happen. So, that when a pleasant thing happens, joy, dopamine, the reward circuit is firing. You see your grandchild, you see your friend. You have a good thing happen. The common bottom line seems to be getting all those different functional areas of the brain to coordinate properly, particularly with top-down control, turning off things that are not appropriate and allowing things that are. When reward circuits are down, people feel apathetic, they feel no interest in things, no drive to pursue things. The last step is making the symptoms go away. Each of the treatments we talked about has a different way of approaching it.— BIRTH NAME: James Earl Carter, Jr. — BORN: Oct. 1, 1924, at the Wise Clinic in Plains, Georgia, the first U.S. president born in a hospital. He would become the first president to live for an entire century . — EDUCATION: Plains High School, Plains, Georgia, 1939-1941; Georgia Southwestern College, Americus, Georgia, 1941-1942; Georgia Institute of Technology, Atlanta, 1942-1943; U.S. Naval Academy, Annapolis, Maryland, 1943-1946 (class of 1947); Union College, Schenectady, New York, 1952-1953. — PRESIDENCY: Sworn-in as 39th president of the United States at the age of 52 years, 3 months and 20 days on Jan. 20, 1977, after defeating President Gerald R. Ford in the 1976 general election. Left office on Jan. 20, 1981, following 1980 general election loss to Ronald Reagan. — POST-PRESIDENCY: Launched The Carter Center in 1982. Began volunteering at Habitat for Humanity in 1984. Awarded Nobel Peace Prize in 2002. Taught for 37 years at Emory University, where he was granted tenure in 2019, at age 94. — OTHER ELECTED OFFICES: Georgia state senator, 1963-1967; Georgia governor, 1971-1975. — OTHER OCCUPATIONS: Served in U.S. Navy, achieved rank of lieutenant, 1946-53; Farmer, warehouseman, Plains, Georgia, 1953-77. — FAMILY: Wife, Rosalynn Smith Carter , married July 7, 1946 until her death Nov. 19, 2023. They had three sons, John William (Jack), James Earl III (Chip), Donnel Jeffrey (Jeff); a daughter, Amy Lynn; and 11 living grandchildren and 14 great-grandchildren. Source: Jimmy Carter Library & Museum

Marvel Rivals - Official Season 0: Dooms' Rise TrailerBig Tech Losses Pull Indexes Down'Just getting started': Gators knock off Rebels